Pirfetablet 267mg Tablet
Manufacturer
Zydus Healthcare Limited
Salt Composition
Pirfenidone (267mg)
Key Information
Short Description
Pirfetablet 267mg Tablet is a prescription medicine used in the treatment of idiopathic pulmonary fibrosis. It reduces scarring and swelling in the lungs and helps to breathe better.
Dosage Form
Tablet
Introduction
Pirfetablet 267mg Tablet is best taken with food. Take it at the same time every day to get the most benefits. The dose and how often you take it depends on what you are taking it for. Your doctor will decide how much you need to improve your symptoms. You should take this medicine for as long as it is prescribed for you. The most common side effects of this medicine include insomnia, headache, dizziness, dyspepsia, nausea, diarrhea, and photosensitivity. To overcome dizziness, avoid driving or attention-seeking activity. Some people may experience weight loss and other side effects. Monitor your weight regularly or ask for the doctor's advice in such cases. Your doctor also may perform a liver function test while on treatment with this medicine.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Pirfetablet 267mg Tablet is to be taken with food.
Safety Information
Side Effects
No common side effects listed.
Alcohol Warning
It is not known whether it is safe to consume alcohol with Pirfetablet 267mg Tablet. Please consult your doctor.
Breastfeeding Warning
Information regarding the use of Pirfetablet 267mg Tablet during breastfeeding is not available. Please consult your doctor.
Pregnancy Warning
Pirfetablet 267mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
How it works
Pirfetablet 267mg Tablet is an antifibrotic medication. It works by blocking the action of a certain natural substance in the body that is involved in causing fibrosis. This reduces the scarring and swelling in the lungs and makes breathing easier.
Quick Tips
Pirfetablet 267mg Tablet reduces scarring and swelling in the lungs and helps you breathe better. It is best to take this medicine with food and at the same time each day. Stop smoking during treatment with Pirfetablet 267mg Tablet as it can reduce the effect of the treatment. It may cause dizziness or sleepiness. Do not drive or do anything requiring concentration until you know how it affects you. It may cause weight loss. Monitor your weight regularly. Your doctor may check your liver function regularly. Inform your doctor if you develop abdominal pain, loss of appetite, darkened urine or yellowing of the eyes or skin (jaundice).
Related Medicines
Frequently asked questions
What monitoring will I need during treatment with Pirfetablet 267mg Tablet?
Your doctor will check your liver function before starting treatment with Pirfetablet 267mg Tablet. This test will be repeated monthly for the first 6 months and then it will be done after every three months. In addition to that, your doctor will also monitor your lung function periodically in order to see the response to Pirfetablet 267mg Tablet.
Why is it important to continue treatment with Pirfetablet 267mg Tablet?
Continuing treatment with Pirfetablet 267mg Tablet is crucial for managing idiopathic pulmonary fibrosis (IPF). It helps preserve lung function, which cannot be restored once lost. Therefore, it's essential to follow the prescribed treatment plan and continue taking this medication as recommended by your doctor.
What are the side effects of Pirfetablet 267mg Tablet?
Common side effects include skin sensitivity to sunlight, nausea, tiredness, diarrhea, indigestion or upset stomach, loss of appetite, and headache. Other common side effects include infections of the throat or airways, bladder infections, weight loss, difficulty sleeping, dizziness, sleepiness, changes in taste, hot flushes, shortness of breath, and cough. Additionally, individuals might experience stomach problems like acid reflux, vomiting, bloating, abdominal pain and discomfort, heartburn, constipation, skin problems such as itchy skin, skin redness or red skin, dry skin, skin rash, muscle pain, aching joints/joint pains, weakness, chest pain, and sunburn. It is possible that after using Pirfetablet 267mg Tablet blood tests may show increased levels of liver enzymes.
Is Pirfetablet 267mg Tablet a steroid?
No, Pirfetablet 267mg Tablet is not a steroid. It belongs to the pyridines group of medicines. It is used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF causes scarring and swelling of the lung tissues over time, which can lead to breathing difficulties. This medicine helps reduce these effects and improve breathing.
How do I know that Pirfetablet 267mg Tablet is right for me?
Only you and your doctor can decide if Pirfetablet 267mg Tablet is right for you. The doctor will assess your condition before prescribing it, based on your response to treatment and tolerability. It's important to continue the medication as recommended by your doctor.
If my disease is stable can I stop Pirfetablet 267mg Tablet?
While idiopathic pulmonary fibrosis (IPF) progression is unpredictable, it may still be progressive. Do not discontinue treatment without consulting your doctor as this will affect the effectiveness of the medication and could potentially slow down its progress.
What should I avoid while taking Pirfetablet 267mg Tablet?
To maximize the effectiveness of Pirfetablet 267mg Tablet, it is important to minimize exposure to sunlight. Wear sunblock daily and cover your arms, legs, and head to reduce sun exposure. Additionally, quitting smoking will also improve its effect.
What is the survival rate of pulmonary fibrosis?
The median survival for patients with pulmonary fibrosis is 2-3 years; however, some individuals can live much longer. Factors that may impact lifespan include age at diagnosis, smoking history, and lower body mass index. Other factors are a more severe extent of disease both radiologically and physically, the development of other lung complications or conditions.
